Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients

Older adult patients are underrepresented in clinical trials comparing non–vitamin K antagonist oral anticoagulants (NOACs) and warfarin. This subgroup analysis of the ARISTOPHANES study used multiple data sources to compare the risk of stroke/systemic embolism (SE) and major bleeding (MB) among very old patients with nonvalvular atrial fibrillation (NVAF) prescribed NOACs or warfarin.

[1]  G. Lip,et al.  Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients , 2018, Stroke.

[2]  C. Coleman,et al.  Effectiveness and safety of rivaroxaban vs. warfarin in patients 80+ years of age with non-valvular atrial fibrillation. , 2018, European heart journal. Quality of care & clinical outcomes.

[3]  M. Corti,et al.  Different safety profiles of oral anticoagulants in very elderly non-valvular atrial fibrillation patients. A retrospective propensity score matched cohort study. , 2018, International journal of cardiology.

[4]  J. Uhm,et al.  Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: A systematic review and meta-analysis. , 2018, Journal of cardiology.

[5]  Ho‐Min Chen,et al.  Dabigatran, Rivaroxaban, and Warfarin in the Oldest Adults with Atrial Fibrillation in Taiwan , 2018, Journal of the American Geriatrics Society.

[6]  T. Chao,et al.  Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study , 2018, Circulation.

[7]  A. Camm,et al.  The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. , 2018, European heart journal.

[8]  P. Hjemdahl,et al.  Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[9]  Yolanda V. Martinez,et al.  Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults – a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing , 2017, BMC Geriatrics.

[10]  G. Lip,et al.  Stroke prevention in atrial fibrillation: Past, present and future , 2017, Thrombosis and Haemostasis.

[11]  N. Marchionni,et al.  Oral anticoagulant therapy for older patients with atrial fibrillation: a review of current evidence. , 2017, European journal of internal medicine.

[12]  G. Sergi,et al.  Appropriateness of Oral Anticoagulants for the Long-Term Treatment of Atrial Fibrillation in Older People: Results of an Evidence-Based Review and International Consensus Validation Process (OAC-FORTA 2016) , 2017, Drugs & Aging.

[13]  Jack Mardekian,et al.  Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice , 2017, Thrombosis and Haemostasis.

[14]  Ya-Hui Hsueh,et al.  Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. , 2016, JAMA internal medicine.

[15]  P. Noseworthy,et al.  Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation , 2016, Journal of the American Heart Association.

[16]  Mark Levenson,et al.  Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation , 2015, Circulation.

[17]  N. Limdi,et al.  Validity of International Classification of Disease Codes to Identify Ischemic Stroke and Intracranial Hemorrhage Among Individuals With Associated Diagnosis of Atrial Fibrillation , 2015, Circulation. Cardiovascular quality and outcomes.

[18]  G. Lip,et al.  New Oral Anticoagulants in Elderly Adults: Evidence from a Meta‐Analysis of Randomized Trials , 2014, Journal of the American Geriatrics Society.

[19]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[20]  D. Atar,et al.  Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial , 2014, European heart journal.

[21]  Lennart Bergfeldt,et al.  Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited: A Population-Based Study , 2013, Stroke.

[22]  P. Austin.  The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments , 2013, Statistics in medicine.

[23]  G. Lip,et al.  Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report , 2012, Chest.

[24]  W. Ray,et al.  An automated database case definition for serious bleeding related to oral anticoagulant use , 2011, Pharmacoepidemiology and drug safety.

[25]  S. Yusuf,et al.  Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial , 2011, Circulation.

[26]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[27]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[28]  P. Austin.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[29]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[30]  L. Fauchier,et al.  Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis , 2018, Age and ageing.

[31]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.